Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ARCT Arcturus Therapeutics Holdings Inc
- Stocks
- Healthcare
- NASDAQ: ARCT
Price (delayed)
$11.86
Market cap
$321.65M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.53
Enterprise value
$105.19M
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™
Highlights
ARCT's quick ratio has surged by 70% year-on-year and by 21% since the previous quarter
The company's EPS rose by 37% YoY and by 16% QoQ
The revenue has grown by 15% year-on-year but it has declined by 6% since the previous quarter
Arcturus Therapeutics Holdings's gross profit has increased by 15% YoY but it has decreased by 6% QoQ
Arcturus Therapeutics Holdings's debt has surged by 56% QoQ and by 41% YoY
ARCT's equity is down by 11% year-on-year and by 3% since the previous quarter
Key stats
What are the main financial stats of ARCT
Market
Valuations
Earnings
Shares outstanding
27.12M
Market cap
$321.65M
Enterprise value
$105.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.38
Price to sales (P/S)
2.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.73
Revenue
$143.68M
Gross profit
$143.68M
Operating income
-$82.08M
Net income
-$68.2M
EBIT
-$83.77M
EBITDA
-$80.33M
Free cash flow
-$89.87M
Per share
Balance sheet
Liquidity
EPS
-$2.53
EPS diluted
-$2.53
Free cash flow per share
-$3.32
Book value per share
$8.62
Revenue per share
$5.3
TBVPS
$12.24
Total assets
$331.79M
Total liabilities
$98.03M
Debt
$38.99M
Equity
$233.76M
Working capital
$229.39M
Debt to equity
0.17
Current ratio
5.64
Quick ratio
5.46
Net debt/EBITDA
2.69
Margins
Efficiency
Dividend
EBITDA margin
-55.9%
Gross margin
100%
Net margin
-47.5%
Operating margin
-57.1%
Return on assets
-19%
Return on equity
-27.4%
Return on invested capital
-276.9%
Return on capital employed
-29.7%
Return on sales
-58.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARCT stock price
How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
2.33%
1 week
5.52%
1 month
22.27%
1 year
-58.7%
YTD
-30.11%
QTD
11.99%
Financial performance
How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$143.68M
Gross profit
$143.68M
Operating income
-$82.08M
Net income
-$68.2M
Gross margin
100%
Net margin
-47.5%
Arcturus Therapeutics Holdings's net margin has increased by 45% YoY and by 11% QoQ
Arcturus Therapeutics Holdings's operating margin has increased by 42% YoY and by 9% QoQ
The net income is up by 36% year-on-year and by 16% since the previous quarter
Arcturus Therapeutics Holdings's operating income has increased by 33% YoY and by 14% QoQ
Price vs fundamentals
How does ARCT's price correlate with its fundamentals
Growth
What is Arcturus Therapeutics Holdings's growth rate over time
Valuation
What is Arcturus Therapeutics Holdings stock price valuation
P/E
N/A
P/B
1.38
P/S
2.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.73
The company's EPS rose by 37% YoY and by 16% QoQ
ARCT's P/B is 57% lower than its 5-year quarterly average of 3.2 and 31% lower than its last 4 quarters average of 2.0
ARCT's equity is down by 11% year-on-year and by 3% since the previous quarter
ARCT's price to sales (P/S) is 94% lower than its 5-year quarterly average of 40.5 and 30% lower than its last 4 quarters average of 3.2
The revenue has grown by 15% year-on-year but it has declined by 6% since the previous quarter
Efficiency
How efficient is Arcturus Therapeutics Holdings business performance
Arcturus Therapeutics Holdings's ROIC has soared by 69% from the previous quarter and by 58% YoY
The company's return on sales rose by 40% YoY and by 8% QoQ
The company's return on equity rose by 29% YoY and by 13% QoQ
The ROA has increased by 23% YoY and by 11% QoQ
Dividends
What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARCT.
Financial health
How did Arcturus Therapeutics Holdings financials performed over time
ARCT's current ratio has soared by 73% YoY and by 21% QoQ
ARCT's quick ratio has surged by 70% year-on-year and by 21% since the previous quarter
Arcturus Therapeutics Holdings's debt is 83% lower than its equity
The debt to equity has soared by 70% from the previous quarter and by 70% YoY
Arcturus Therapeutics Holdings's debt has surged by 56% QoQ and by 41% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.